Trials / Terminated
TerminatedNCT02040558
Trial to Study the Safety of Intravenous MNK-010 in Advanced Solid Tumors
A Multicenter, Open-Label, Phase 1 First in Human Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous MNK-010 in Subjects With Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Mallinckrodt · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open-label, dose escalation study of MNK-010 in subjects with advanced solid malignancies who have failed conventional therapy. The safety, tolerability, pharmacokinetic (PK) profile, and preliminary antitumor activity of ascending doses of MNK-010 will be evaluated in subjects with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MNK-010 |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2016-05-01
- Completion
- 2016-07-01
- First posted
- 2014-01-20
- Last updated
- 2017-04-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02040558. Inclusion in this directory is not an endorsement.